The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer

Selvi, İsmail; Başar, Halil; Baydilli, Numan; Murat, Koza; Kaymaz, Özlem

doi:10.1007/s11255-019-02261-8

Cited by 16 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer(PCa) is one of the most common cancers among males in the world and the fifth most common malignancy in the general population 1 . Serum prostate‐specific antigen (PSA) testing is the most commonly used test for the diagnosis and screening of PCa 2 .…”

Section: Introductionmentioning

confidence: 99%

C‐reactive protein and procalcitonin levels in prostate cancer

2020

View full text Add to dashboard Cite

Aim Prostate cancer (PCa) is one of the most common cancers among men in the world. Prostate‐specific antigen is the most used biomarker for PCa diagnosis. In this study, we aimed to measure the procalcitonin (PCT) and C‐reactive protein (CRP) levels in patients with PCa. Methods The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign prostate hyperplasia and group2; prostate cancer. MedCalc Statistical Software version 17.6 was used for statistical analyses. Results The current study includes 149 patients. There were 118 patients in group 1 and 31 patients in group 2. The mean age of the patients was 66.85 and 69.41 years in groups respectively. Serum CRP and PCT levels were 3.33 and 0.01 in group 4.07 and 0.04 in group 2. Serum PCT levels were significantly higher in patients with PCa. Conclusion We found that the elevated procalcitonin level was associated with prostate cancer. Further studies are needed to define the relationship between procalcitonin and prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

C‐reactive protein and procalcitonin levels in prostate cancer

2020

View full text Add to dashboard Cite

show abstract

“…Key Words: prostate cancer, procalcitonin, C-reactive protein Introduction: Prostate cancer(PCa) is one of the most common cancer among males in the world and the fifth most common malignancy in the general population (1). Serum prostate specific antigen (PSA) testing is the most commonly used test for the diagnosis and screening of PCa (2).…”

mentioning

confidence: 99%

“…The patients may be diagnosed as from clinically indolent to metastatic disease (3).Digital rectal examination (DRE) and PSA testing are important for early diagnosis of PCa (4). Unfortunatelly PSA is not cancer specific marker, it is organ specific; so elevated levels are seen in benign diseases such as prostatitis, benign prostate hyperplasia and urinary retention (1,4).Despite its adequate sensitivity, the use of PSA testing is limited and additional serum testing derivated from PSA ( PSA density, free/total PSA, PSA velocity) and new biomarkers (prostatehealthindex, fourkallikrein and procalcitonin) were investigated for diagnosis of PCa (2,4,5). C-reactive protein (CRP) is an acute-phase proteinwhich is produced in the liver (6).…”

mentioning

confidence: 99%

“…Serum PSA testing is the most widely accepted and used biomarker for prostatic diseases especially PCa (9). But PSA is not cancer specific marker, increases in benign prostate diseases and there is no threshold value of PSA for cancer diagnosis (1). In general PSA over 4 ng/ml is recommended for biopsy, the cancer detection rate is between 20-25% in patients with a PSA value of 4-10 ng/ml.…”

mentioning

confidence: 99%

“…In our previous study, the cancer detection rate was 22.3, 34.5 and 54.2% in patients with PSA level of 4-10, 10.01-20 and 20.01-50 ng/ml respectively (10). To reduce the unnecessary biopsies; new molecules and markers which have higher positive predictive value than PSA have been investigated (1). Prostate health index, four kallikrein score test, PSA density and velocity, free/total PSA ratio, PCA3 marker was used to differentiate benign prostate diseases from PCa(4).We found that free/total PSA ratio has significant diagnostic efficacy for PCa diagnosis in PSA level 4.01-10 ng/ml (5).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Can procalcitonin be a new biomarker in prostate cancer? Preliminary results

İlktaç

Kalkan

kan³

2020

Preprint

View full text Add to dashboard Cite

Aim: Prostate cancer (PCa) is one of the most common cancer among men in the world. Prostate specific antigen is the most used biomarker for PCa diagnosis. In this study we aimed to measure the procalcitonin(PCT) and C-reactive protein (CRP) levels in patients with PCa. Methods: The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign prostate hyperplasia and group2; prostate cancer. MedCalc Statistical Software version 17.6 was used for statistical analyses. Results: The current study includes 149 patients. There were 118 patients in group1 and 31 patients in group 2. The mean age of the patients was 66.85 and 69.41 years in groups respectively. Serum CRP and PCT levels was 3.33 and 0.01 in group 4.07 and 0.04 in group 2. Serum PCT levels was significantly higher in patients with PCa. Conclusion: We found that elevated procalcitonin levels was associated with prostate cancer. Further studies are needed to define the relationship between procalcitonin and prostate cancer. What's Known: Prostate cancer is the second most common cancer among elderly men. Prostate specific antigen testisng is usually used in screening and diagnosis. Unfortunately PSA is not cancer specific and new biomarkers are needed for prostate cancer management. What's New: Procalcitonin is a precursor of calcitonin which is produced by thyroid C-cells and some neuroendocrine cells. The elevated level of procalcitonin is associated with bacteremia and sepsis. In this study e investigated the procalcitonin levels in prostate cancer. C-reactive protein and Procalcitonin levels in Prostate Cancer Aim: Prostate cancer (PCa) is one of the most common cancer among men in the world. Prostate specific antigen is the most used biomarker for PCa diagnosis. In this study we aimed to measure the procalcitonin(PCT) and C-reactive protein (CRP) levels in patients with PCa. Methods: The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign prostate hyperplasia and group2; prostate cancer. MedCalc Statistical Software version 17.6 was used for statistical analyses. Results: The current study includes 149 patients. There were 118 patients in group1 and 31 patients in group 2. The mean age of the patients was 66.85 and 69.41 years in groups respectively. Serum CRP and PCT levels was 3.33 and 0.01 in group 4.07 and 0.04 in group 2. Serum PCT levels was significantly higher in patients with PCa.

show abstract